Stock DNA
Pharmaceuticals & Biotechnology
SEK 224 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
1.10
-40.18%
1.33
Revenue and Profits:
Net Sales:
129 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.49%
0%
-24.49%
6 Months
-24.49%
0%
-24.49%
1 Year
-24.49%
0%
-24.49%
2 Years
-24.49%
0%
-24.49%
3 Years
-82.65%
0%
-82.65%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Boule Diagnostics AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.24%
EBIT Growth (5y)
-208.64%
EBIT to Interest (avg)
-2.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.04
Sales to Capital Employed (avg)
1.13
Tax Ratio
17.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.64%
ROE (avg)
5.22%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.20
EV to EBIT
-1.16
EV to EBITDA
-1.24
EV to Capital Employed
1.09
EV to Sales
0.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-94.25%
ROE (Latest)
-172.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
129.30
137.00
-5.62%
Operating Profit (PBDIT) excl Other Income
12.80
7.70
66.23%
Interest
6.50
3.30
96.97%
Exceptional Items
-4.50
0.00
Consolidate Net Profit
-5.70
-1.60
-256.25%
Operating Profit Margin (Excl OI)
52.60%
23.40%
2.92%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -5.62% vs -2.49% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -256.25% vs -139.02% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
558.50
571.30
-2.24%
Operating Profit (PBDIT) excl Other Income
-263.90
67.90
-488.66%
Interest
12.50
11.30
10.62%
Exceptional Items
-56.30
0.00
Consolidate Net Profit
-296.60
25.00
-1,286.40%
Operating Profit Margin (Excl OI)
-513.60%
75.70%
-58.93%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.24% vs 4.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -1,286.40% vs 96.85% in Dec 2023
About Boule Diagnostics AB 
Boule Diagnostics AB
Pharmaceuticals & Biotechnology
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
Company Coordinates 
Company Details
Domnarsvgatan 4 , SPANGA None : 163 53
Registrar Details






